Belite Bio (NASDAQ:BLTE – Get Free Report) and Tyra Biosciences (NASDAQ:TYRA – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.
Profitability
This table compares Belite Bio and Tyra Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Belite Bio | N/A | -13.14% | -12.88% |
| Tyra Biosciences | N/A | -42.66% | -39.79% |
Valuation and Earnings
This table compares Belite Bio and Tyra Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Belite Bio | N/A | N/A | -$77.61 million | ($2.53) | -57.75 |
| Tyra Biosciences | N/A | N/A | -$119.95 million | ($2.18) | -12.99 |
Belite Bio is trading at a lower price-to-earnings ratio than Tyra Biosciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Belite Bio has a beta of -1.24, suggesting that its share price is 224% less volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500.
Insider & Institutional Ownership
0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 84.1% of Tyra Biosciences shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 12.5% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current recommendations and price targets for Belite Bio and Tyra Biosciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Belite Bio | 1 | 1 | 6 | 0 | 2.63 |
| Tyra Biosciences | 1 | 1 | 12 | 1 | 2.87 |
Belite Bio currently has a consensus target price of $203.00, suggesting a potential upside of 38.93%. Tyra Biosciences has a consensus target price of $47.00, suggesting a potential upside of 65.96%. Given Tyra Biosciences’ stronger consensus rating and higher probable upside, analysts plainly believe Tyra Biosciences is more favorable than Belite Bio.
Summary
Tyra Biosciences beats Belite Bio on 8 of the 12 factors compared between the two stocks.
About Belite Bio
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
About Tyra Biosciences
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Receive News & Ratings for Belite Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Belite Bio and related companies with MarketBeat.com's FREE daily email newsletter.
